Rapidly develop antibody therapeutics when every day matters
Move from patient sample to functional sequences in just 18 days.
Within months of the onset of the worldwide COVID-19 pandemic, the Berkeley Lights Platform was used to identify lead molecules that bind and block the interaction of SARS-CoV-2 virus proteins with their human cell receptors.
Two of these antibodies comprise AstraZeneca’s antibody cocktail now in Phase III Clinical Trials.
Putting function first to select lead antibody candidates in 1 day
Using the Opto™ Viral Neutralization workflow, scientists at Vanderbilt University were able to functionally characterize tens of thousands of individual B cells recovered from patient samples in a single day. This allowed them to deliver sequences of confirmed neutralizing antibodies to downstream manufacturing partners in 18 days.
These antibodies are now part of AstraZeneca’s Phase III clinical trial.
Berkeley Lights Opto Viral Neutralization workflow
CLONING
Clone tens of thousands of B cells into pico-liter sized NanoPen™ chambers on a microfluidic chip.
FUNCTIONAL CHARACTERIZATION
Perform multiple fluorescence-based assays on the same cell to determine antigen specificity, cross-reactivity, and function.
cDNA SYNTHESIS
Simplify downstream sequence recovery with on-chip mRNA capture and cDNA synthesis.
SEQUENCE RECOVERY
Recover sequences of high-value, functionally characterized lead candidates.
Take a behind the scenes look at how Vanderbilt characterized COVID-19 antibodies:
Want to learn more about the Opto Viral Neutralization workflow? Just fill out the short form below and our product specialist will reach out within 24 hours.
Related Resources
View All Antibody Discovery ResourcesWebinar: Accelerating Antibody Discovery in the Modern Therapeutic Landscape
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.
Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.